熱門資訊> 正文
Ironwood因与不良相关的挑战而在杰富瑞降级
2025-04-16 00:10
- Ironwood Pharmaceuticals (NASDAQ:IRWD) has been downgraded to Hold from Buy at Jefferies after the company announced pressures related to its lead asset, apraglutide.
- The company announced Monday that it has decided to evaluate strategic alternatives after the FDA required an additional Phase 3 trial to secure approval for its apraglutide.
- The downgrade by Jefferies reflects increased uncertainty around the drug’s development timeline and approval prospects, with analysts saying that while they previously viewed apraglutide’s clinical profile as a strength, the need for another pivotal study introduces a delay in potential approval, now expected no earlier than 2029, and adds regulatory and financial uncertainty.
- Jefferies has lowered its PT to $0.70 from $8 per share.
More on Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
- Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript
- Ironwood looks for strategic options after regulatory hurdle for lead drug
- Ironwood Pharmaceuticals announces Nasdaq non-compliance notice
- Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals
推薦文章
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
美股機會日報 | 6月零售數據高於市場預期；臺積電績后漲超3%
美股「七巨頭」迎特朗普關稅后首次大考！Q2能否交出亮眼成績單，繼續引領美股上漲？
華盛早報丨TACO交易再現！特朗普閃電改口「解僱鮑威爾」；美國眾議院加密貨幣立法進程受阻
財報前瞻 | 特斯拉Q2營收料下滑10%！股價銷量雙殺下，馬斯克能否逆轉局勢？
美股機會日報 | 低於市場預期！美國6月PPI同比增長2.3%；特斯拉官宣Model Y L
華盛早報丨事關中美關税！美財長最新放風；「加密周」突發！多項加密貨幣法案遭眾議院否決
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
